Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials - Test2 - elhamkhani - TriplyDB

Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials

Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials

http://www.wikidata.org/entity/Q27007856

about

What do general practitioners know about ADHD? Attitudes and knowledge among first-contact gatekeepers: systematic narrative review.Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial.Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder Real-time fMRI neurofeedback in adolescents with attention deficit hyperactivity disorder.The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.Sleep Problems in Children with Attention Deficit/Hyperactivity Disorder: Current Status of Knowledge and Appropriate Management.Methylphenidate use and school performance among primary school children: a descriptive study.Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.A 6-year follow-up of a large European cohort of children with attention-deficit/hyperactivity disorder-combined subtype: outcomes in late adolescence and young adulthood Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system.Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity.Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder.Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater.Evidence on methylphenidate in children and adolescents with ADHD is in fact of 'very low quality'.Methylphenidate-induced obsessive-compulsive symptoms: A case report and review of literature.Long-term methylphenidate intake in chronic fatigue syndrome.Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD.The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder.Non-diagnostic based approaches to helping children who could be labelled ADHD and their families.Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies.Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: a fully blinded, randomized, placebo-controlled trial.Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015.Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder.Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.How to improve psychiatric services: a perspective from critical psychiatry.The Home Observation Measure of the Environment is associated with symptoms of ADHD and oppositionality in a CAMHS sample.Combined Modality Intervention for ADHD With Comorbid Reading Disorders: A Proof of Concept Study.SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.Vitamin D supplementation for chronic liver diseases in adults.A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms.What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder?ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate.Acute and long-term effects of adolescent methylphenidate on decision-making and dopamine receptor mRNA expression in the orbitofrontal cortex.Risks of Stimulant Use for Attention Deficit Hyperactivity Disorder on the Developing Brain: Primum non nocere.ADHD Symptoms in Adolescents' Everyday Life: Fluctuations and Symptom Structure Within and Between Individuals.Attention-deficit/hyperactivity disorder medication and seizures.Attention-Deficit/Hyperactivity Disorder.Methylphenidate HCL for the treatment of ADHD in children and adolescents.Rationale for Dietary Antioxidant Treatment of ADHD.

P2860

Q27313606-54F91397-4731-4BD9-9BA5-1A67524D4B6E Q30843197-285AA0BE-1E6F-4647-822B-969035D22719 Q31146596-AD109A6F-74D9-4AFA-B7A6-69374E012EF5 Q33571522-AC490622-253B-48FF-872E-C5F43BA2D50D Q33697918-5747CE1B-3C97-4ACE-A813-3FD2EBDA500C Q33898415-C8A9776B-1FC1-4B3E-82A7-454036E065E8 Q34677664-FD058B45-1AEC-46FA-BB1A-03871D94C903 Q36327312-B175CE9D-C14B-4E58-93EF-02636F310889 Q36406224-8B69D342-2BBB-4F4E-8254-07DA361BCE4E Q37188220-8A79E990-2D13-4054-8765-07C532D5E89A Q37648289-CEB42DBC-F8D9-4AAF-A9E5-F423124742B8 Q38663434-B1C690A6-B97F-44A4-9499-F04DE645081D Q38827483-81C0A38A-A016-4AB8-A14E-C45DC8DAEBB3 Q39034236-A0F7E8C8-A918-4095-81F7-3A10181134E1 Q39034239-9A173921-30EC-4DC3-A241-D763ED86C505 Q39143576-0A6A2F58-08A7-4469-A652-8AC53F1429DA Q39170713-84ED9371-4795-4A6A-BD3A-E8302D23230B Q39311750-75E3970C-1282-44E7-B59D-7603DDE6EEF8 Q39433708-CF2FB431-D916-428A-BE5A-3C111B62F87F Q41013450-93D90791-8488-4D03-AD9D-376D59AB6F6A Q42363348-3FC4E142-4770-4B26-964A-4CA505049C4D Q42694387-7F0C2BA2-1550-4316-A09B-A682261C4D30 Q42695474-27783102-DAF8-446E-99C2-6555D0FC57BA Q46584563-52BD6465-83BD-41BA-A418-F2B2644D47C9 Q47112969-CC8349ED-AE26-4B97-A925-2BD164D51F87 Q47272210-BD9E1649-E47A-416B-9D4E-C1CD9FFA4515 Q47562341-F44D84FA-C46D-4952-AF04-3DD75A7480B2 Q47620686-0765E452-D696-46BF-82BD-3CA4B4B080A7 Q47644292-14050346-6AFB-410D-AF1B-2207D4DBEB80 Q47663614-38D8021B-11D1-4F0B-AF5E-28476F685BA6 Q47744651-1AD4D2BE-C99F-422C-BBEE-1C6573B042E8 Q47806652-B08261F9-442E-4555-9296-82DE367570CC Q47852087-AB848B06-3D62-4F02-88CF-8B360B82B060 Q48303711-7E1D477C-51E2-406A-8B96-A9201DE801D4 Q50440637-2F2E523F-3C45-4288-9A1A-B81AB6C53C2E Q50532319-63CD6C1D-9142-40D4-B9A9-1DAE5CBB7ED1 Q52687706-4D76C557-92AF-4EA4-BEC4-864E7644CF6B Q52695372-B4261CF0-660E-40C0-A64C-3247D919ECDC Q53736992-42BCE251-C10C-4257-9EDE-27C051CAD491 Q55266001-E27849D1-C4DC-4921-B140-B6A76C4CB694

P2860

Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials

http://www.wikidata.org/entity/Q27007856

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Methylphenidate for attention- ...... of randomised clinical trials

@ast

Methylphenidate for attention- ...... of randomised clinical trials

@en

Methylphenidate for attention- ...... of randomised clinical trials

@nl

type

label

Methylphenidate for attention- ...... of randomised clinical trials

@ast

Methylphenidate for attention- ...... of randomised clinical trials

@en

Methylphenidate for attention- ...... of randomised clinical trials

@nl

prefLabel

Methylphenidate for attention- ...... of randomised clinical trials

@ast

Methylphenidate for attention- ...... of randomised clinical trials

@en

Methylphenidate for attention- ...... of randomised clinical trials

@nl

P1433

Q27007856-92B4B339-19D9-46ED-9BA7-A865A52FF0D6

P1476

Q27007856-737FF2B1-12B8-4E0E-945B-FC0C7EF4E541

P2093

Q27007856-11491E9D-C1DE-4F62-8BE5-F6DFCAA09DCA

Q27007856-32AB6DAD-FCA6-4494-802D-F70E105845A5

Q27007856-3B28C486-1F4B-49AE-A0EF-D2C9985B7239

Q27007856-4F97720D-55CD-4811-A3A8-73FB46895A11

Q27007856-55809847-2832-495C-B520-A3DC7DEE8C62

Q27007856-8C5666FF-61CE-457D-858B-2C0A7CE8757D

Q27007856-931DEAB3-C06F-417A-9132-1B7FFCA3905E

Q27007856-B1AD7B26-8E46-4AE3-A042-0EF5A2E83EAE

Q27007856-B7361147-67A2-4EDD-9DC9-FF6A9428F443

Q27007856-BF69E92D-E41E-4C7A-AB8A-28E141562F37

P275

Q27007856-E0DBA4A8-A101-4B92-8A31-F3303B49B572

P2860

Q27007856-015B9775-0F55-46B0-AEE2-BB55794FC946

Q27007856-037CA19F-35E7-4BEC-8050-450D7DD6F797

Q27007856-064E4D18-C6E9-4AC9-8CFF-638690D1AA33

Q27007856-08068199-1052-47CA-AB06-ABA4D011E494

Q27007856-08E82BE8-690F-47B4-8A45-AA7E66CF50AE

Q27007856-0A272F9D-AB5F-42B9-B54A-3BEA71D37934

Q27007856-1C469064-3C1C-459D-A99E-02BAB1CD677F

Q27007856-2D86F2A3-5703-4807-AB4F-50D43E0016E7

Q27007856-2F6FA8D6-95F3-4FEE-BE1B-1230C9454920

Q27007856-36D7A6B6-C683-4034-BA87-337AFE26D35D

P304

Q27007856-C0381B32-0605-4E5A-9E18-EB4F601FF419

P31

Q27007856-1C37BF92-5921-423A-8F68-4860693EF2A5

Q27007856-78301163-2879-4849-918F-8B67BC3CD442

Q27007856-E1004426-281C-46D2-B553-87F384848CD9

P3181

Q27007856-BF9E7B24-ED1C-41F1-982A-13BF4367D090

P356

Q27007856-069B279C-B6A7-4CAB-9C90-B9E482B938DF

P407

Q27007856-3AD5FDAA-6E64-47B9-AF5A-5C942173E83C

P478

Q27007856-A63BB960-8321-4BB9-8784-2875518F8584

P50

Q27007856-10B078F9-6934-4A2A-8063-A71D5917ECB4

Q27007856-2A13022A-8785-49C9-9649-FC3C9F9B9132

Q27007856-3C540737-522D-4159-B6DA-A4DCC8A82A69

Q27007856-49F28F83-A3EF-4F06-BDBD-609917101098

Q27007856-7816A677-E299-441A-897A-E64250F75BF2

Q27007856-7E00CE6C-4F29-4865-9649-916F015E7BFD

Q27007856-A4258629-0A69-4AA3-8F67-7182A65EE66B

P5008

Q27007856-75E6DC0D-9CA5-4291-8A57-22A48EA94434

P577

Q27007856-41047B1E-F77B-451F-AAF1-7A0D8B19328C

P5875

Q27007856-630FD78C-EF54-4C61-BDC6-7DA4847AC784

P698

Q27007856-63F9D70C-F3A0-40A4-8FB4-4F749A770E2C

P921

Q27007856-3370122B-B06C-47AD-BC09-BF8D86E3C6CA

Q27007856-3E8BCA88-72C5-44C8-BF9E-37962963C732

Q27007856-44F3C38D-F1EF-4D45-AAFA-B4DFECAA5EB7

Q27007856-49340B8B-B476-4D07-8272-BEB5A93E6A41

Q27007856-91003DCA-EEE4-4EE1-918F-E35042F00845

Q27007856-B940955F-44A8-4F7E-94C0-508C5CE2BE6E

Q27007856-F1903BA5-DAF8-47EF-BE39-9172DD6CD187

P932

Q27007856-4A08676B-0CCD-41A5-A3FE-064445926C0A

P3181

P356

P1433

P1476

Methylphenidate for attention- ...... of randomised clinical trials

@en

P2093

Bente Forsbøl

http://www.w3.org/2001/XMLSchema#string

Camilla Groth

http://www.w3.org/2001/XMLSchema#string

Carlos R Moreira-Maia

http://www.w3.org/2001/XMLSchema#string

Erica Ramstad

http://www.w3.org/2001/XMLSchema#string

Frederik L Magnusson

http://www.w3.org/2001/XMLSchema#string

Helle B Krogh

http://www.w3.org/2001/XMLSchema#string

Mathilde Holmskov

http://www.w3.org/2001/XMLSchema#string

Morris Zwi

http://www.w3.org/2001/XMLSchema#string

Ole Jakob Storebø

http://www.w3.org/2001/XMLSchema#string

Susanne Rosendal

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults

Industry sponsorship and research outcome

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

Comparing the efficacy of medications for ADHD using meta-analysis

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

P304

h5203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

3646218

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/BMJ.H5203

http://www.w3.org/2001/XMLSchema#string

P407

P478

351

http://www.w3.org/2001/XMLSchema#string

P50

Christian Gluud

Kirsten Buch Rasmussen

Richard Kirubakaran

P5008

P577

2015-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284719332

http://www.w3.org/2001/XMLSchema#string

P698

26608309

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

attention deficit hyperactivity disorder

heterocyclic compound

P932

4659414

http://www.w3.org/2001/XMLSchema#string